.Attribute Medication, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research, after a mean consequence of 11 months, clients with metastatic gastrointestinal cysts that received biomarker-matched therapies based upon distributing tumor DNA profiling presented a greater clinical benefit than those getting incomparable therapy.